Stockscreener 앱 받기
2.15
3.15%
-0.07
시간 외 거래:
2.18
0.03
+1.40%
전일 마감가:
$2.22
열려 있는:
$2.2
하루 거래량:
452.66K
Relative Volume:
1.04
시가총액:
$60.96M
수익:
-
순이익/손실:
$-28.85M
주가수익비율:
-1.5334
EPS:
-1.4021
순현금흐름:
$-25.62M
1주 성능:
-19.48%
1개월 성능:
-22.38%
6개월 성능:
+9.14%
1년 성능:
+16.22%
1일 변동 폭
$2.11
$2.24
1주일 범위
$2.11
$2.72
52주 변동 폭
$1.11
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
명칭
Annovis Bio Inc
전화
484-875-3192
주소
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.15 | 62.95M | 0 | -28.85M | -25.62M | -1.4021 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2024-10-25 | 업그레이드 | Maxim Group | Hold → Buy |
| 2023-12-29 | 개시 | Canaccord Genuity | Buy |
| 2021-07-07 | 재확인 | Maxim Group | Buy |
Annovis Bio Inc 주식(ANVS)의 최신 뉴스
Annovis Partners With NeuroRPM to Add AI Monitoring in PD Study - MyChesCo
Annovis Bio, Inc. Files Form 8-K with NYSE Listing and Corporate Information for March 23, 2026 - Minichart
Annovis Bio CFO departs, CEO appointed as acting CFO By Investing.com - Investing.com Canada
Biopharmaceutical company Annovis Bio Inc announced that its CEO Maria Maccecchini will temporarily serve as CFO until the company finds a permanent replacement. - Bitget
Annovis Bio's Mark Guerin departs as CFO; Maria Maccecchini to serve as Acting CFO - TradingView
CFO departs Annovis Bio (ANVS) as CEO Maria Maccecchini takes acting finance role - Stock Titan
Annovis Bio Secures Full Patent Protection for New Crystal Form of Alzheimer’s Drug Buntanetap - MSN
Annovis Reports 2025 Results, Advances Buntanetap Trials - MyChesCo
If You Invested $1,000 in Annovis Bio Inc (ANVS) - Stock Titan
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Market Rankings: Will Annovis Bio Inc stock recover after earnings2026 Chart Watch & High Conviction Buy Zone Picks - baoquankhu1.vn
Meme Stocks: Will Annovis Bio Inc benefit from rising consumer demand2026 Short Interest & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Annovis Bio Publishes Data on New Crystal Form of Lead Alzheimer’s Drug - MSN
NeuroRPM Partners with Annovis for Parkinson's Disease Monitoring - Intellectia AI
Annovis Bio partners with NeuroRPM for Parkinson’s trial monitoring By Investing.com - Investing.com India
Annovis Bio partners with NeuroRPM for Parkinson’s trial monitoring - Investing.com
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial - markets.businessinsider.com
Neurorpm To Deploy Ai-Enabled Digital Biomarker Monitoring For Annovis Bio's Parkinson's Disease Clinical Trial - TradingView
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study - The Manila Times
Wearables track Parkinson's symptoms in Annovis drug study - Stock Titan
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia - MSN
Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference - MSN
Shorts Report: Is Annovis Bio Inc stock forming a triangle pattern2026 Gainers & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Chart Watch: Should you avoid Annovis Bio Inc stock right now2026 Performance Recap & Low Risk High Win Rate Picks - baoquankhu1.vn
ANVS Technical Analysis & Stock Price Forecast - Intellectia AI
Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients - MSN
Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan
Annovis Bio shares are trading higher. The company reported Q4 financial results.Annovis Bio (NYSE:ANVS) - Benzinga
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results - Bitget
Annovis Bio, Inc. Announces Business Updates and Financial Results for Fiscal Year 2025, Highlighting Pivotal Advances in Buntanetap Development for Neurodegenerative Diseases - Quiver Quantitative
Annovis Bio Q4 EPS $(0.39) Misses $(0.34) EstimateAnnovis Bio (NYSE:ANVS) - Benzinga
Alzheimer’s oral drug buntanetap enters pivotal trial, 3‑year PD study - Stock Titan
Annovis Bio (ANVS) Stock Analysis Report | Financials & Insights - Benzinga Japan
Annovis Bio to present buntanetap clinical data at AD/PD 2026 conference - MSN
Annovis Bio (NYSE: ANVS) outlines late-stage Alzheimer’s and Parkinson’s program - Stock Titan
Annovis Bio’s Buntanetap: Advancing Clinical Development for Alzheimer’s and Parkinson’s Disease with Novel Multi-Targeted Approach 33 - Minichart
Annovis Bio (NYSE:ANVS) Releases Earnings Results, Misses Expectations By $0.08 EPS - MarketBeat
Annovis Bio 10-K: Net loss $28.9M; Cash $19.5M, runway into Q3 2026 - TradingView
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Friday - MarketBeat
Annovis Bio, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
ANVS|Annovis Bio Inc|Price:2.490|Chg%:-0.09 - TradingKey
Published on: 2026-03-11 14:44:25 - baoquankhu1.vn
Annovis Bio to Present Buntanetap Clinical Data at AD/PD 2026 Conference - MyChesCo
Support Test: Is Annovis Bio Inc. stock technically oversold2026 WrapUp & Technical Confirmation Trade Alerts - baoquankhu1.vn
Annovis Bio Secures NYSE Approval to Regain Compliance with Listing Standards - MSN
Momentum Shift: What makes Annovis Bio Inc stock attractive todayM&A Rumor & Fast Gain Stock Tips - baoquankhu1.vn
Annovis Bio Stock Price Drops 8.5%What's Next? - National Today
Annovis Bio (NYSE:ANVS) Stock Price Down 8.5%What's Next? - MarketBeat
Annovis CEO eyes spring breakthrough for Alzheimer’s drug - Longevity.Technology
Annovis Bio Inc (ANVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.04%
0.06%
자본화:
|
볼륨(24시간):